Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Himalaya Nutravedics IPO
Price Band
₹100.0–106.0
Issue Size
₹26.5 Cr
Lot Size
1,200 shares
Min Investment
₹254,400
2 LOTS MIN
GMP
—
Issue Price
₹106.0
Himalaya Nutravedics IPO AI Summary
- Himalaya Nutravedics IPO is allotted on BSE SME in the Other Food Products sector.
- Price band: ₹100.0–₹106.0 per share, lot size 1,200 shares (min. investment ₹254,400, 2 lots minimum).
- Subscription window: 22 Sep–24 Sep 2026, listing on 29 Sep 2026.
Himalaya Nutravedics is an emerging player in the Ayurvedic and nutraceutical market, with a strong growth trajectory in revenue and profit. The company operates a hybrid business model and has a diversified product portfolio. The IPO offers an opportunity for investors to participate in its growth, with a reasonable valuation compared to peers.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Important Dates
Subscription Status
Overall Subscription
2.33x
| Category | Subscription | Status |
|---|---|---|
| QIB (Institutional) |
1.00x
|
1.00x |
| NII (HNI) |
3.58x
|
3.58x |
| ↳ bNII (>₹10L) |
3.84x
|
3.84x |
| ↳ sNII (<₹10L) |
3.04x
|
3.04x |
| Retail (RII) |
2.56x
|
2.56x |
| Total | 2.33x | 2.33x |
Auto-updated every 5 min · As of 24th Sep 2026 18:56
Himalaya Nutravedics IPO Grey Market Premium (GMP) Today
GMP not available yet
Grey Market Premium is updated daily. Check back closer to the listing date.
TopFund Score — Listing Data Indicator
GMP is 0.0% above issue price
QIB subscribed 1.0x
No anchor allocation for this IPO
Similar IPOs (same sector & type) averaged 48.0% listing gain
A rules-based composite of GMP, subscription demand, anchor participation and comparable-IPO history — each weighted as shown above. Not a statistically validated probability, a guarantee of listing performance, or personalized investment advice.
Limitations: weights are fixed by TopFund, not backtested against outcomes; the "Historical Similar-IPO Performance" factor needs at least 3 comparable past listings and falls back to a broader, less specific cohort when this sector/type doesn't have enough; GMP and subscription data can change daily right up to listing day, so scores shown may already be stale — check the "as of" date above.
About the Company
Himalaya Nutravedics India Ltd is engaged in the manufacturing, marketing, and distribution of Ayurvedic and nutraceutical formulations in India. In addition to its own branded products, the company also undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical companies. It offers a diversified product portfolio that includes classical Ayurvedic formulations based on traditional texts, proprietary Ayurvedic products, and nutraceutical supplements. These are available in multiple dosage forms such as soft gelatin capsules, hard gelatin capsules, tablets, liquid orals, and medicated oils. The company operates through a hybrid business model, balancing its own-brand formulations with contract manufacturing services. It has an integrated in-house manufacturing facility located in Hyderabad, Telangana. As of September 2025, its products are distributed across multiple states in India, with a strong revenue presence in Telangana, Andhra Pradesh, Kerala, Gujarat, and Uttar Pradesh. Its product portfolio spans a wide range of wellness and therapeutic segments, including digestive health, immunity, metabolic health, musculoskeletal and joint care, reproductive health, respiratory wellness, pain management, and general well-being. These formulations are designed to support general wellness, nutritional supplementation, and lifestyle-related health needs, in line with applicable regulatory standards. Competitive Strengths: Integrated multi-dosage manufacturing capability Doctor acceptance supported by product performance rather than mass advertising Long-standing relationships with suppliers and customers Geographic expansion achieved over a relatively short operating history Broad therapeutic coverage across ayurvedic and nutraceutical segment
Company Financials (₹ Cr)
As of 2026-03-31
| Period Ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 24.42 | 10.82 | 6.09 |
| Total Income | 43.12 | 21.00 | 14.43 |
| Profit After Tax | 7.39 | 2.23 | 0.43 |
| EBITDA | 8.10 | 2.99 | 0.94 |
| NET Worth | 16.38 | 6.75 | 1.34 |
| Reserves and Surplus | 10.07 | 2.76 | 0.53 |
| Total Borrowing | 5.13 | 1.76 | 3.24 |
Key Ratios
EPS
₹11.72
NAV
₹26.70
ROE
63.87%
ROCE
36.41%
RoNW
45.12%
P/B Value
3.97
P/E Ratio
9.04
Market Cap
₹93.35 Cr
PAT Margin
17.16%
Debt/Equity
0.31
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| Sandu Pharmaceuticals Ltd. | 45.21 | 2.53% | 20.62 | 1.83 | 1.83 |
| Jeena Sikho Lifecare Ltd. | 37.6 | 27.67% | 26.75 | 17.84 | 17.81 |
| Himalaya Nutravedics India Ltd. This IPO | 26.7 | 45.12% | — | 12.05 | 12.05 |
Promoters
Rohit Asawa, Divya Asawa, Chanda Asawa, Rama Raju Penmatsa
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Funding Working Capital Requirements 13.75 2 Business Development and Digital Marketing Activities 7.50 3 General Corporate Purposes Total 21.25
IPO Evaluation
Generated 27 Sep 2026Revenue Trend
Revenue was ₹14.43 Cr in the year ending 31 Mar 2024, rising to ₹21.00 Cr by 31 Mar 2025, and further increasing to ₹43.12 Cr by 31 Mar 2026. This shows a strong upward trend in total income over the periods.
Profit Trend
Profit After Tax was ₹0.43 Cr in the year ending 31 Mar 2024, increasing to ₹2.23 Cr by 31 Mar 2025, and further rising to ₹7.39 Cr by 31 Mar 2026. This indicates substantial growth in profitability over the reported periods.
Valuation
Priced at roughly 9.04 trailing earnings, versus peers trading at a P/E range of 20.62-26.75.
Grey Market Premium, Explained
The Grey Market Premium (GMP) is an unofficial indicator of the expected listing price of an IPO. It reflects the demand and supply dynamics in the grey market and can provide insights into investor sentiment before the official listing. However, GMP is not a guaranteed predictor of actual listing gains.
Subscription Demand
The IPO has received a total subscription of 2.33 times as of 24th Sep 2026. The breakdown includes 1.0 times from Qualified Institutional Buyers (QIB), 3.58 times from Non-Institutional Investors (NII), and 2.56 times from Retail Individual Investors (RII).
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their overall investment strategy and risk tolerance. It is advisable to consider the company's growth potential and market position.
Who May Want to Wait
Investors with a low-risk appetite or those seeking guaranteed short-term returns may want to avoid IPOs like this, as they can be subject to market fluctuations and uncertainties.
IPO Timeline, Explained
The IPO opens for subscription on 22nd September 2026 and closes on 24th September 2026. Allotment of shares will be done on 25th September 2026, with the listing expected on 29th September 2026.
Listing Gains — The Risk
Listing-day gains can be unpredictable and depend on various factors such as market conditions, investor sentiment, and overall demand for the stock. Investors should be cautious and not rely solely on potential listing gains when making investment decisions.
This evaluation is generated from Himalaya Nutravedics's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is the price band of Himalaya Nutravedics IPO?
The price band of Himalaya Nutravedics IPO is ₹100.0–₹106.0 per share.
When does Himalaya Nutravedics IPO open and close?
Himalaya Nutravedics IPO opens on 22 September 2026 and closes on 24 September 2026.
When does Himalaya Nutravedics IPO list on the stock exchange?
Himalaya Nutravedics IPO is scheduled to list on 29 September 2026, with an estimated listing price of ₹106.0 based on current GMP.
What is the lot size for Himalaya Nutravedics IPO?
The lot size for Himalaya Nutravedics IPO is 1200 shares, requiring a minimum investment of ₹254,400 (2 lots).
What is the TopFund Listing Data Indicator for Himalaya Nutravedics?
Himalaya Nutravedics's Listing Data Indicator score is 45/100 (Moderate signal), a weighted composite of GMP strength, subscription demand, anchor investor interest and how similar past IPOs performed on listing. It's a rules-based summary of public market data, not a statistically validated probability, a guarantee, or personalized investment advice.
What is the price band for the Himalaya Nutravedics IPO?
The price band for the Himalaya Nutravedics IPO is ₹100.0 to ₹106.0.
What is the minimum investment required for this IPO?
The minimum investment required for this IPO is ₹254,400.
What is the lot size for the Himalaya Nutravedics IPO?
The lot size for the Himalaya Nutravedics IPO is 1200 shares.
When is the listing date for the Himalaya Nutravedics IPO?
The listing date for the Himalaya Nutravedics IPO is 29th September 2026.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected price of the IPO on its listing day based on unofficial trading in the grey market.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
22 Sep 2026
Close
24 Sep 2026
Allotment
25 Sep 2026
Listing
29 Sep 2026
Similar IPOs in Other Food Products
Plan Your IPO Investment
Related Articles
Full Analysis
Should you apply? Company analysis, GMP explained & FAQs
Community Sentiment
What are other investors planning for Himalaya Nutravedics?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.